| Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial 2019 · Group I · Infertile women with polycystic ovarian syndrome (PCOS) | 1.8 g | 90 days | 60 |
| Effects of Ziziphus jujuba, metformin, and myoinositol on pregnancy rates and metabolic parameters in infertile women with PCOS: a randomized controlled trial 2026 · Myoinositol + Placebo · Women aged 18–45 with PCOS and infertility | 2 g | 12 weeks | 49 |
| Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial 2021 · Group II · Infertile women with polycystic ovarian syndrome undergoing ovulation induction cycles; age and sex details beyond women not reported | 4 g | 26 weeks | 59 |
| Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial 2021 · Group I · Infertile women with polycystic ovarian syndrome undergoing ovulation induction cycles; age and sex details beyond women not reported | 4 g | 26 weeks | 57 |
| Myoinositol versus metformin pretreatment in GnRH-antagonist cycle for women with PCOS undergoing IVF: a double-blinded randomized controlled study 2022 · group 1 (Myo) · Infertile women with PCOS undergoing IVF; age and sex-specific details beyond women are not reported | 4 g | 90 days | 50 |
| A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia 2016 · myo-inositol group · Current and former smokers aged 45–79 years with at least a 30 pack-year smoking history and at least one histologically confirmed site of bronchial dysplasia | 18 g | 26 weeks | 44 |
| The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios 2019 · DCI alone · Women with polycystic ovary syndrome (PCOS); age not reported | 4 g | 90 days | 8 |
| Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial 2019 · study group (SG) · Women with PCOS undergoing ICSI; age not reported | 1.4 g | 12 weeks | — |
| The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial 2023 · myo-inositol group · Overweight pregnant women at 12–14 weeks of gestation | 2 g | 10 weeks | — |
| Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial 2011 · D-chiro-inositol group · Euglycemic patients with PCOS undergoing ovulation induction for ICSI; age and sex not otherwise specified | 1.2 g | — | 41 |
| Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial 2015 · myo-inositol · Pregnant obese women (prepregnancy BMI 30 or greater) | 4 g | — | 110 |
| Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial 2016 · myo-inositol group · Pregnant overweight, non-obese women with pre-pregnancy BMI ≥25 and <30 kg/m² | 4 g | — | 110 |
| Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: an open-label, randomized controlled trial 2024 · MI group · Pregnant women at 11–13+6 weeks of gestation | 4 g | — | 100 |
| Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women 2010 · MYO plus folic acid, with r-FSH added if no pregnancy occurred · Women with polycystic ovary syndrome, menstrual irregularities, chronic anovulation, and female infertility; ages not reported | 4 g | — | 60 |
| myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study 2013 · myo-inositol group · Pregnant women recruited at 12–13 weeks’ gestation with a first-degree relative with type 2 diabetes, prepregnancy BMI <30 kg/m², and no pregestational diabetes or PCOS | 4 g | — | — |
| Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial 2019 · control group (CG) · Women with PCOS undergoing ICSI; age not reported | 1.13 g | 12 weeks | — |
| Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial 2003 · inositol · Women with oligomenorrhea and polycystic ovaries (PCOS) | 200 mg | 14 weeks | 136 |
| Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial 2011 · MyoInositol group · Euglycemic patients with PCOS undergoing ovulation induction for ICSI; age and sex not otherwise specified | 4 g | — | 43 |
| Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder 1995 · inositol · 21 patients with panic disorder, with or without agoraphobia | 12 g | 4 weeks | 21 |
| Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder 2001 · inositol · Adults with panic disorder | 18 g | 30 days | 20 |
| Double-blind, controlled trial of inositol treatment of depression 1995 · inositol · depressed patients; age and sex not reported | 12 g | 4 weeks | 13 |
| Inositol treatment of obsessive-compulsive disorder 1996 · inositol · patients with obsessive-compulsive disorder | 18 g | 6 weeks | 13 |
| Inositol as an add-on treatment for bipolar depression 2000 · inositol · Adult men and women with DSM-IV bipolar depression (21 with bipolar I and 3 with bipolar II) | 12 g | 6 weeks | 12 |
| Effect of inositol on bulimia nervosa and binge eating 2001 · inositol · 12 patients with bulimia nervosa and binge eating | 18 g | 6 weeks | 12 |
| Inositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trial 1996 · inositol · 11 patients with Alzheimer's disease | 6 g | 30 days | 11 |
| The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome 2011 · OCP plus myo-inositol · Patients with polycystic ovary syndrome; age and sex not specified | 4 g | 1 year | — |
| Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study 2022 · MI + DCI · Young women aged 15–24 years with PCOS and delayed menstrual cycles | 1.4 g | 26 weeks | — |
| Follow-up and relapse analysis of an inositol study of depression 1995 · inositol · Patients with depression; age and sex not reported | 12 g | — | — |
| Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus 2012 · pinitol · Adults with type 2 diabetes who had been taking oral hypoglycemic agents for at least 3 months | 1.2 g | — | 33 |
| Higher Plasma Myo-Inositol in Pregnancy Associated with Reduced Postpartum Blood Loss: Secondary Analyses of the NiPPeR Trial 2024 · intervention supplement · Women aged 18–38 years planning conception; those included in this analysis conceived and had a singleton live birth | 4 g | — | 293 |
| The effect of myo-inositol, vitamin D3 and melatonin on the oocyte quality and pregnancy in in vitro fertilization: a randomized prospective controlled trial 2020 · Study group · Women undergoing ICSI | 3.2 g | 26 weeks | 50 |
| Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS 2007 · myo-inositol plus folic acid · Women with oligomenorrhea and polycystic ovaries | 4 g | 14 weeks | 45 |
| A Prospective Study Evaluating the Effects of a Nutritional Supplement Intervention on Cognition, Mood States, and Mental Performance in Video Gamers 2019 · study supplement (nooLVL) · Healthy, non-smoking video gamers aged 18–40 years who played video games at least 5 hours per week | 100 mg | 7 days | 30 |
| [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition] 2012 · diet, metformin and MYO (D+M+I) · Overweight or obese women with polycystic ovary syndrome; age not reported | 4 g | 90 days | 9 |
| Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study 2006 · myoinositol/folic acid combination · men with type 2 diabetes and erectile dysfunction | 4 g | — | — |
| Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial 2011 · Group A · Women with polycystic ovary syndrome undergoing IVF | 4 g | 90 days | — |
| The myo-inositol effect on the oocyte quality and fertilization rate among women with polycystic ovary syndrome undergoing assisted reproductive technology cycles: a randomized clinical trial 2019 · study group · infertile women with PCOS undergoing assisted reproductive technology cycles; age not reported | 4 g | 30 days | — |
| The impact of myo-inositol supplementation on sleep quality in pregnant women: a randomized, double-blind, placebo-controlled study 2022 · myo-inositol supplementation · Pregnant women with low-risk singleton pregnancies, at least 14 weeks’ gestation | 2 g | 10 weeks | — |
| Improvement in biochemical manifestations of the serum and follicular fluid and ICSI outcomes in PCOS patients with myo-inositol administration: prospective randomized research 2025 · MI group · Infertile women with PCOS undergoing ovulation induction for ICSI; age not reported | 4 g | 6 weeks | — |
| Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study 2011 · intervention group · Postmenopausal women with metabolic syndrome | 4 g | 26 weeks | — |
| A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes 2017 · treated group · Overweight or obese patients with type 1 diabetes receiving intensive insulin therapy | 1 g | 24 weeks | — |
| Impact of preconception and antenatal supplementation with myo-inositol, probiotics, and micronutrients on offspring BMI and weight gain over the first 2 years 2024 · Intervention group · Offspring of women aged 18–38 years recruited while planning pregnancy; mothers received the supplement before conception and during pregnancy | 4 g | — | 287 |
| Infant body composition in a randomised trial of a maternal nutritional supplement during preconception and pregnancy 2025 · Intervention · Women receiving the NiPPeR preconception and pregnancy intervention; offspring were followed during the first two years of life | 4 g | — | 268 |
| Efficacy and Safety of "URSA Complex" in Subjects with Physical Fatigue: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial 2016 · URSA Complex · Adults older than 19 with persistent or chronic fatigue for at least 1 month and a baseline CIS score of at least 76; both sexes | 20 mg | 4 weeks | 81 |
| Effectiveness of a Food Supplement Based on Glucomannan, D-Chiro-Inositol, Cinnamomum zeylanicum Blume and Inulin in Patients with Metabolic Syndrome 2024 · oral supplement group · Adults over 18 with overweight and metabolic syndrome, including people with type 2 diabetes or impaired glucose tolerance; men and women | 40 mg | 16 weeks | 29 |
| A phytotherapic approach to reduce sperm DNA fragmentation in patients with male infertility 2017 · group A (Tradafertil) · men with previously diagnosed male infertility | 1 g | 90 days | — |
| Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome 2002 · D-chiro-inositol group · Lean women with polycystic ovary syndrome, BMI 20.0–24.4 kg/m² | 600 mg | 8 weeks | 10 |
| Inositol for the prevention of neural tube defects: a pilot randomised controlled trial 2016 · young-adult research staff volunteers · Young-adult research staff volunteers, men and non-pregnant women | 1.3 g | 7 days | 10 |
| Effectiveness of dual combination therapy of acarbose plus metformin and acarbose plus myo-inositol in ameliorating the metabolic and endocrinologic complications of polycystic ovary syndrome - A randomized controlled trial 2024 · Group C · Women with polycystic ovary syndrome; age range not stated | 2 g | 26 weeks | 54 |
| Efficacy of myoinositol in treatment of gestational diabetes mellitus in Asian Indian women: A pilot randomized clinical trial 2021 · myoinositol group · Pregnant Asian Indian women with singleton pregnancies and gestational diabetes diagnosed between 14 and 28 weeks’ gestation | 2 g | 123 days | 50 |
| Daily phytate intake increases adiponectin levels among patients with diabetes type 2: a randomized crossover trial 2023 · InsP6-diet group · Adults aged 18 years or older with type 2 diabetes, stable glycemic control, and low dietary InsP6 intake; 23 women and 16 men completed the study | 1.14 g | 12 weeks | 39 |
| Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study 2017 · MYO (myoinositol) · Women aged 25–30 with obesity and polycystic ovary syndrome | 2 g | 26 weeks | 34 |
| Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome 1999 · D-chiro-inositol · Obese women with polycystic ovary syndrome | 1.2 g | 7 weeks | 22 |
| Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome 2012 · MYO · Normal-weight women with polycystic ovary syndrome | 1.2 g | 12 weeks | 18 |
| Effects of pinitol isolated from soybeans on glycaemic control and cardiovascular risk factors in Korean patients with type II diabetes mellitus: a randomized controlled study 2005 · pinitol · Korean patients with type II diabetes mellitus | 1.2 g | 13 weeks | — |
| Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial 2019 · low-dose group · Adults with ultrasonography-proven non-alcoholic fatty liver disease; age and sex not reported | 300 mg | 12 weeks | — |
| Pinitol consumption improves liver health status by reducing oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial 2019 · high-dose group · Adults with ultrasonography-proven non-alcoholic fatty liver disease; age and sex not reported | 500 mg | 12 weeks | — |
| One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome 2012 · myo-inositol · postmenopausal women with metabolic syndrome | 4 g | 1 year | 40 |
| Effect of consumption of a carob pod inositol-enriched beverage on insulin sensitivity and inflammation in middle-aged prediabetic subjects 2016 · Inositol-enriched beverage (IEB) · Middle-aged adults with impaired fasting glucose (fasting glucose 100–125 mg/dL), grouped by BMI | 4 g | 12 weeks | 24 |
| Myo-inositol and melatonin in the menopausal transition 2017 · myo-inositol group · Women aged 45–55 years with at least 6 months of amenorrhea during the menopausal transition | 4 g | 26 weeks | 20 |
| Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial 2018 · DCI treatment · Pregnant women with gestational diabetes mellitus | 500 mg | 8 weeks | 20 |
| Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome 2008 · DCI group · Women aged 18–40 with polycystic ovary syndrome, chronic oligomenorrhea and hyperandrogenemia | 2.4 g | 6 weeks | 6 |
| High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial 2020 · high DCI content group · Women with PCOS undergoing ICSI | 850 mg | 12 weeks | 5 |
| A single acute dose of pinitol from a naturally-occurring food ingredient decreases hyperglycaemia and circulating insulin levels in healthy subjects 2013 · 2.5 g pinitol beverage · healthy subjects | 2.5 g | 1 day | — |
| A single acute dose of pinitol from a naturally-occurring food ingredient decreases hyperglycaemia and circulating insulin levels in healthy subjects 2013 · 4.0 g pinitol beverage · healthy subjects | 4 g | 1 day | — |
| A single acute dose of pinitol from a naturally-occurring food ingredient decreases hyperglycaemia and circulating insulin levels in healthy subjects 2013 · 6.0 g pinitol beverage · healthy subjects | 6 g | 1 day | — |
| Chronic consumption of an inositol-enriched carob extract improves postprandial glycaemia and insulin sensitivity in healthy subjects: A randomized controlled trial 2016 · inositol-enriched beverage (IEB) · healthy subjects; age and sex not specified | 4.46 g | 12 weeks | — |
| Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS) 2017 · myo-inositol · Women with PCOS and insulin resistance and/or hyperinsulinemia | 4 g | 26 weeks | — |
| The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial 2022 · MI (myo-inositol) · Women with polycystic ovary syndrome (PCOS), including normal-weight and overweight/obese women; ages not reported | 4 g | 26 weeks | — |
| Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study 2022 · intervention (myo-inositol) · Pregnant women aged at least 16 years with a singleton pregnancy at 12+0 to 15+6 weeks’ gestation and high risk of gestational diabetes | 4 g | — | 99 |
| Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS 2014 · D-chiro-inositol group · Women with PCOS and menstrual irregularities | 1 g | 26 weeks | 25 |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception | 4 g | — | 870 |
| Myoinositol plus α-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study 2021 · Treated group · Women aged 18–44 with gestational diabetes mellitus and a singleton pregnancy | 4 g | 60 days | 60 |
| Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: A randomized controlled trial 2020 · Group A · Poor responder patients undergoing ICSI; age and sex details not reported | 4 g | — | 56 |
| Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial 2023 · arm-2 · Women aged 20–35 years with obesity and oligo-anovulatory PCOS | 2 g | 12 weeks | 55 |
| Inositol for the prevention of neural tube defects: a pilot randomised controlled trial 2016 · inositol+FA group · Women aged 18–40 planning pregnancy, with a history of a previous neural tube defect-affected pregnancy | 1 g | — | 25 |
| The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes 2011 · study group · Women with gestational diabetes treated with diet | 4 g | 8 weeks | 24 |
| Myo-inositol and melatonin in the menopausal transition 2017 · myo-inositol plus melatonin group · Women aged 45–55 years with at least 6 months of amenorrhea during the menopausal transition | 2 g | 26 weeks | 20 |
| Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial 2018 · MI treatment · Pregnant women with gestational diabetes mellitus | 4 g | 8 weeks | 20 |
| Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial 2018 · MI plus DCI treatment · Pregnant women with gestational diabetes mellitus | 1.13 g | 8 weeks | 20 |
| Effect of Myo-Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study 2025 · Group 1 · Pregnant women aged 18–40 without the stated exclusion conditions | 4 g | 21 weeks | 20 |
| Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome 2008 · Group A · Overweight patients with polycystic ovary syndrome; age and sex details not stated | 2 g | 12 weeks | 10 |
| Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study 2013 · Group A · Overweight patients with polycystic ovary syndrome; age and sex not specified | 2 g | 12 weeks | 10 |
| High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial 2020 · low DCI content group · Women with PCOS undergoing ICSI | 578 mg | 12 weeks | 6 |
| Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome 2016 · Group A · Women of reproductive age with polycystic ovarian syndrome undergoing IVF | 4 g | — | — |
| Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome 2016 · Group B · Women of reproductive age with polycystic ovarian syndrome undergoing IVF | 4 g | — | — |
| Efficacy of myo-inositol and zinc on insulin resistance in a paediatric population with obesity 2025 · TRT · Patients aged 10–18 years with obesity and insulin resistance | 2 g | 90 days | — |
| The ameliorative effect of myo-inositol on apoptosis-related genes expression in cumulus cells of women with polycystic ovary syndrome undergoing ICSI and its relationship with the quality of oocyte and embryo 2025 · MYO group · Infertile women with PCOS undergoing ICSI; age range and sex beyond women not reported | 4 g | 6 weeks | — |
| Myo-Inositol, Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial 2021 · Intervention · Women aged 18–38 planning to conceive within 6 months; recruited primarily from the community and followed through pregnancy. | 4 g | — | 870 |
| Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS 2014 · Myo-inositol group · Women with PCOS and menstrual irregularities | 4 g | 26 weeks | 25 |
| The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole 2019 · Group III · Infertile women with polycystic ovary syndrome who did not ovulate after letrozole treatment | 4 g | 90 days | — |